HK1038025A1 - Novel anti-diabetic peptides - Google Patents
Novel anti-diabetic peptidesInfo
- Publication number
- HK1038025A1 HK1038025A1 HK01108592A HK01108592A HK1038025A1 HK 1038025 A1 HK1038025 A1 HK 1038025A1 HK 01108592 A HK01108592 A HK 01108592A HK 01108592 A HK01108592 A HK 01108592A HK 1038025 A1 HK1038025 A1 HK 1038025A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diabetes
- type
- compounds
- treating
- activities
- Prior art date
Links
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000055006 Calcitonin Human genes 0.000 abstract 2
- 108060001064 Calcitonin Proteins 0.000 abstract 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 2
- 229960004015 calcitonin Drugs 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 229940127438 Amylin Agonists Drugs 0.000 abstract 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000446 fuel Substances 0.000 abstract 1
- 230000005176 gastrointestinal motility Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/138,056 US6087334A (en) | 1998-08-21 | 1998-08-21 | Anti-diabetic peptides |
| PCT/US1999/017918 WO2000011029A2 (en) | 1998-08-21 | 1999-08-09 | Novel anti-diabetic peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1038025A1 true HK1038025A1 (en) | 2002-03-01 |
Family
ID=22480238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK01108592A HK1038025A1 (en) | 1998-08-21 | 2001-12-06 | Novel anti-diabetic peptides |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6087334A (xx) |
| EP (1) | EP1104438B1 (xx) |
| JP (1) | JP2002523424A (xx) |
| AT (1) | ATE354590T1 (xx) |
| AU (1) | AU766545B2 (xx) |
| CA (1) | CA2337971C (xx) |
| DE (1) | DE69935229T2 (xx) |
| ES (1) | ES2283127T3 (xx) |
| HK (1) | HK1038025A1 (xx) |
| WO (1) | WO2000011029A2 (xx) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143718A (en) | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| AU2001293557A1 (en) * | 2000-09-19 | 2002-04-02 | University Of Toronto | New inhibitors of iapp fibril formation and uses thereof |
| CA2475173A1 (en) * | 2002-01-08 | 2003-07-17 | Amylin Pharmaceuticals, Inc. | Use of amylin agonists to modulate triglycerides |
| SI1494732T1 (sl) | 2002-03-20 | 2008-08-31 | Mannking Corp | Inhalacijski aparat |
| US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
| WO2006083254A1 (en) | 2004-02-11 | 2006-08-10 | Amylin Pharmaceuticals, Inc. | Amylin family peptides and methods for making and using them |
| US7399744B2 (en) * | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
| JP5078014B2 (ja) | 2004-08-20 | 2012-11-21 | マンカインド コーポレイション | ジケトピペラジン合成の触媒反応 |
| HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
| EP1807442A1 (en) * | 2004-10-26 | 2007-07-18 | Lonza Ag | S-alkyl-sulphenyl protection groups in solid-phase synthesis |
| EP1888043A4 (en) * | 2005-03-11 | 2010-07-28 | Endo Pharmaceuticals Solutions | OCTREOTIDE FORMULATIONS WITH CONTROLLED RELEASE |
| US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
| ATE480255T1 (de) * | 2005-03-31 | 2010-09-15 | Amylin Pharmaceuticals Inc | Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen |
| EP1928423B1 (en) | 2005-09-14 | 2015-12-09 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| EP1986679B1 (en) | 2006-02-22 | 2017-10-25 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| US20090181890A1 (en) * | 2006-03-31 | 2009-07-16 | Amylin Pharmaceuticals , Inc. | Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders |
| ES2389747T3 (es) | 2007-02-05 | 2012-10-31 | Amylin Pharmaceuticals, Inc. | Péptidos FN-38 para su uso en el tratamiento de desórdenes psicóticos y de ansiedad |
| KR101736535B1 (ko) * | 2007-10-24 | 2017-05-16 | 맨카인드 코포레이션 | Ｇｌｐ-1에 의한 유해 효과의 예방 방법 |
| KR101558026B1 (ko) | 2008-06-13 | 2015-10-06 | 맨카인드 코포레이션 | 건조 분말 흡입기 및 약물 투여 시스템 |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| CA2728523C (en) | 2008-06-20 | 2020-03-10 | Mannkind Corporation | An interactive apparatus and method for real-time profiling of inhalation efforts |
| UA104866C2 (uk) | 2008-06-25 | 2014-03-25 | Ендо Фармас'Ютікалз Солюшнз Інк. | Імплантат октреотиду, який містить вивільняючу речовину |
| JP5622725B2 (ja) * | 2008-06-25 | 2014-11-12 | エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． | エキセナチド及び他のポリペプチド類の持続的送達 |
| TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US8538707B2 (en) | 2009-03-11 | 2013-09-17 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| CA2755068C (en) * | 2009-03-12 | 2018-11-06 | Nordic Bioscience A/S | Treatment of diabetes and metabolic syndrome |
| EP2440184B1 (en) | 2009-06-12 | 2023-04-05 | MannKind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
| CA2801936C (en) | 2010-06-21 | 2021-06-01 | Mannkind Corporation | Dry powder drug delivery system and methods |
| KR101940832B1 (ko) | 2011-04-01 | 2019-01-21 | 맨카인드 코포레이션 | 의약 카트리지용 블리스터 패키지 |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| EP2776053A1 (en) | 2011-10-24 | 2014-09-17 | MannKind Corporation | Methods and compositions for treating pain |
| EP2841089A4 (en) | 2012-04-03 | 2016-03-16 | Univ Boston | COMPOSITIONS, PROCESSES AND ASSAYS WITH AMYLIN OR AMLYANANALOGA FOR ABETA PEPTIDE-MEDIATED ILLNESSES |
| CA2878457C (en) | 2012-07-12 | 2021-01-19 | Mannkind Corporation | Dry powder drug delivery systems and methods |
| EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
| WO2014144895A1 (en) | 2013-03-15 | 2014-09-18 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| BR122019026637B1 (pt) | 2013-07-18 | 2023-09-26 | Mannkind Corporation | Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco |
| WO2015021064A1 (en) | 2013-08-05 | 2015-02-12 | Mannkind Corporation | Insufflation apparatus and methods |
| WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
| DK3143037T3 (da) | 2014-05-16 | 2021-09-20 | Protagonist Therapeutics Inc | Alpha4beta7-integrin-thioether-peptidantagonister |
| RU2736637C9 (ru) | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника |
| WO2016054445A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| JP2017535527A (ja) | 2014-10-01 | 2017-11-30 | プロタゴニスト セラピューティクス， インコーポレイテッド | 新規のα４β７ペプチド単量体及び二量体拮抗薬 |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| KR101669140B1 (ko) * | 2015-04-28 | 2016-10-26 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| CA3073806A1 (en) | 2017-09-11 | 2019-03-14 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP3997105A4 (en) | 2019-07-10 | 2023-09-13 | Protagonist Therapeutics, Inc. | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES |
| CN118005737A (zh) | 2020-01-15 | 2024-05-10 | 詹森生物科技公司 | 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途 |
| CA3202226A1 (en) | 2020-11-20 | 2022-05-27 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8709871D0 (en) * | 1987-04-27 | 1987-06-03 | Turner R C | Peptides |
| GB8720115D0 (en) * | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
| US5814600A (en) * | 1991-05-24 | 1998-09-29 | Amylin Pharmaceuticals Inc. | Method and composition for treatment of insulin requiring mammals |
| US5965528A (en) * | 1991-09-27 | 1999-10-12 | Mcgill University | Recombinant human alph-fetoprotein as an immunosuppressive agent |
| CA2120131A1 (en) * | 1991-09-27 | 1994-05-11 | Robert A. Murgita | Expression and purification of cloned human alpha-fetoprotein |
| HUT70176A (en) * | 1993-05-12 | 1995-09-28 | Univ Cincinnati | Amylin antagonists and agonists |
| US5625032A (en) * | 1993-07-21 | 1997-04-29 | Amylin Pharmaceuticals, Inc. | Selective amylin antagonist peptides and uses therefor |
| US6143718A (en) * | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
-
1998
- 1998-08-21 US US09/138,056 patent/US6087334A/en not_active Expired - Lifetime
-
1999
- 1999-08-09 CA CA2337971A patent/CA2337971C/en not_active Expired - Fee Related
- 1999-08-09 DE DE69935229T patent/DE69935229T2/de not_active Expired - Lifetime
- 1999-08-09 WO PCT/US1999/017918 patent/WO2000011029A2/en active IP Right Grant
- 1999-08-09 AT AT99939073T patent/ATE354590T1/de not_active IP Right Cessation
- 1999-08-09 ES ES99939073T patent/ES2283127T3/es not_active Expired - Lifetime
- 1999-08-09 JP JP2000566301A patent/JP2002523424A/ja active Pending
- 1999-08-09 EP EP99939073A patent/EP1104438B1/en not_active Expired - Lifetime
- 1999-08-09 AU AU53430/99A patent/AU766545B2/en not_active Ceased
-
2001
- 2001-12-06 HK HK01108592A patent/HK1038025A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1104438B1 (en) | 2007-02-21 |
| CA2337971C (en) | 2011-04-26 |
| AU5343099A (en) | 2000-03-14 |
| ES2283127T3 (es) | 2007-10-16 |
| AU766545B2 (en) | 2003-10-16 |
| DE69935229T2 (de) | 2007-11-08 |
| JP2002523424A (ja) | 2002-07-30 |
| DE69935229D1 (de) | 2007-04-05 |
| ATE354590T1 (de) | 2007-03-15 |
| WO2000011029A2 (en) | 2000-03-02 |
| CA2337971A1 (en) | 2000-03-02 |
| US6087334A (en) | 2000-07-11 |
| EP1104438A2 (en) | 2001-06-06 |
| WO2000011029A3 (en) | 2000-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1038025A1 (en) | Novel anti-diabetic peptides | |
| CA2116478A1 (en) | Prolonged delivery of peptides | |
| GR3035150T3 (en) | Compounds with growth hormone releasing properties | |
| MY136926A (en) | Glucokinase activators | |
| GEP20074144B (en) | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | |
| JO2034B1 (en) | Isotopes of the hormone peptide its uses and the chemical compounds it contains | |
| BG103264A (en) | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | |
| DE3362003D1 (de) | Mammalian pgrf | |
| MXPA02005536A (es) | Acidos aminopropilfosfinicos novedosos. | |
| YU41199A (sh) | Hinoksalindioni | |
| IL146868A0 (en) | A pharmaceutical composition containing an igf-i/igfbp-3 complex | |
| IL115966A (en) | Neuroprotective pharmaceutical compositions comprising GDNF | |
| ATE238689T1 (de) | ZUSAMMENSETZUNG DIE EINEN ALPHA-AMYLASE INHIBITOR UND MINDESTENS EINE PHYSIOLOGISCH AKZEPTABELE KOMPONENTE, DER DIE INTESTINALE ABSORPTION VON ßFAST SUGARSß REDUZIEREN KANN, ENTHÄLT | |
| EP1053001A4 (en) | NEW COMPOUNDS WITH MIXED AMYLIN ACTIVITY | |
| PE20030361A1 (es) | Formulaciones en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas | |
| CA2344686A1 (en) | High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one | |
| AU2796395A (en) | Process for melting a metal charge in a rotary kiln, and rotary kiln for implementing such process | |
| BG104062A (en) | Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor | |
| GR3034549T3 (en) | Anhydrous composition comprising lactulose | |
| AP1418A (en) | Novel composition and emulsifier. | |
| IE37131L (en) | Insulin derivatives. | |
| UA15356A (uk) | Композиція для одержаhhя вогhезахисhого покриття | |
| UA88862C2 (xx) | Аналоги глюкагоноподібного пептиду-1[аналоги глюкагоподобного пептида-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20100809 |